CSIMarket
 
Beam Therapeutics Inc   (NASDAQ: BEAM)
Other Ticker:  
 
 
Price: $21.4600 $1.16 5.714%
Day's High: $22.39 Week Perf: 7.95 %
Day's Low: $ 20.86 30 Day Perf: 25.13 %
Volume (M): 3,984 52 Wk High: $ 35.25
Volume (M$): $ 85,501 52 Wk Avg: $23.72
Open: $21.76 52 Wk Low: $13.53



 Market Capitalization (Millions $) 1,765
 Shares Outstanding (Millions) 82
 Employees 190
 Revenues (TTM) (Millions $) 64
 Net Income (TTM) (Millions $) -377
 Cash Flow (TTM) (Millions $) -155
 Capital Exp. (TTM) (Millions $) 9

Beam Therapeutics Inc


   Company Address: 238 Main Street Cambridge 2142 MA
   Company Phone Number: 327-8775    Stock Exchange / Ticker: NASDAQ BEAM


Customers Net Income fell by BEAM's Customers Net Profit Margin fell to

-30.3 %

7.67 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CRSP     
DNA     
EDIT     
KRYS     
PLX     
RGNX     
• View Complete Report
   



Product Service News

Beam Therapeutics Reports Promising Data for BEAM-302 in AATD Amidst Financial Challenges

Published Sat, Apr 5 2025 11:20 PM UTC

Beam Therapeutics, a prominent player in the gene-editing sector, has released promising new data on its investigational therapy, BEAM-302, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) at the 7th Global Research Conference and 10th Patient Congress organized by the Alpha-1 Foundation. The company reported that in the 60 mg cohort (n=3), the treatment led to a...

Clinical Study

Promising Advances in Sickle Cell Disease Treatment Beam Therapeutics Unveils BEAM-101 Trial Data Amidst Financial Ch...

Published Sat, Dec 7 2024 4:30 PM UTC

Beam Therapeutics Inc. has made significant strides in the treatment of sickle cell disease, presenting groundbreaking new data from its BEACON Phase 1/2 clinical trial of BEAM-101 during the recent American Society of Hematology (ASH) Annual Meeting. Notably, all seven patients who received BEAM-101 displayed remarkable results: a hemoglobin F (HbF) induction exceeding 60%,...

Clinical Study

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle C...

Published Tue, Nov 5 2024 2:00 PM UTC

Advancements in Hematology: Beam Therapeutics Innovative Research Amidst Financial Challenges Beam Therapeutics, a leading biotechnology company focused on developing precision genetic medicines through base editing, recently made significant presentations at the American Society of Hematology (ASH) Annual Meeting. The data presented encapsulates crucial insights from thei...

Clinical Study

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency ...

Published Wed, Jun 26 2024 10:30 AM UTC

Beam Therapeutics Groundbreaking BEAM-302 Enters Clinical Trial for Alpha-1 Antitrypsin Deficiency, While Suppliers Face Financial ChallengesConclusion:Beam Therapeutics Inc. s dosing of the first patient with BEAM-302 in the Phase 1/2 clinical trial for severe alpha-1 antitrypsin deficiency represents a significant advancement in precision genetic medicines. The therapy s ...

Clinical Study

Beam Therapeutics Optimized Manufacturing Process Boosts Sickle Cell Disease Therapy Development

Published Fri, Jun 14 2024 7:00 AM UTC

Beam Therapeutics, a leading biotechnology company specializing in precision genetic medicines through base editing, has announced significant progress in the manufacturing process for BEAM-101, an investigational base editing therapeutic for sickle cell disease (SCD). The company presented data at the European Hematology Association (EHA) Hybrid Congress, highlighting the s...







Beam Therapeutics Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com